Sartorius Stedim Biotech SASartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL04-Aug-2026 / 10:11 CET/CESTDissemination of a French Regulatory News, transmitted by EQS Group.The issuer is solely responsible for the content of this…
Profitable growth continued in H1 2026, led by high-margin consumables and services, with all regions contributing and strong recovery in Asia. Underlying EBITDA margin improved to 31.4%, and management confirmed full-year guidance and new mid-term growth targets.Original document: Sartorius Stedim…
Sales revenue grew 6.4% in constant currencies, with strong recurring business and robust profitability. Management confirmed 2026 guidance, expecting 6–10% sales growth and a slightly higher EBITDA margin, despite tariff-related adjustments.Original document: Sartorius Stedim Biotech SA [DIM] Earn…
Sartorius Stedim Biotech SASartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech03-Jul-2026 / 10:03 CET/CESTDissemination of a French Regulatory News, transmitted by EQS Group.The issuer is solely responsible for the content of this announcement.Aubagne, J…
Sartorius Stedim Biotech might narrow its full-year sales guidance when it reports second-quarter results in a few weeks, Bernstein's Delphine Le Louet and Susannah Ludwig say in a research note. "We think the company will probably narrow its sales guidance up to the high end from 6-10% to 8-10%,"…
